Skip to content
OpenCapital
Get started

Kura Oncology KURA Q4 2025 Annual earnings

Reported March 5, 2026 · Before market open

Revenue$17.3MMiss by $18.1MDiluted EPS-$0.92Miss by $0.20
Revenue estimate$35.4M
EPS estimate-$0.72

Next report

Aug 6, 2026 (In 3 weeks)
Revenue estimate$20.2M
EPS estimate-$0.89

Financials

Q4 2025

Income statement

See full
Revenue$17.3M+28.7%
Operating income-$86.3M-284%
Net income-$81.0M-321%
EPS (diluted)-$0.92-318%

Balance sheet

See full
Cash & equivalents$149.1M-33.6%
Total debt$20.5M+23.3%
Total equity$174.1M-57.9%
Total assets$738.4M-2.9%

Cash flow

See full
CapEx$2.3M+524%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$904.11M+33.5%
Enterprise value$775.47M+65.2%
P/S13.4×+0.8×

Profitability

See full
Operating margin-449.9%+154pp
Net margin-412.9%+160pp

Returns & leverage

See full
Return on equity-94.8%-547pp
Debt / equity0.1×+0.1×
Current ratio6.1×-3.4×

Versus estimates

Revenue

Q1 2026$18.3MMiss by $7.7M
Q4 2025$17.3MMiss by $18.1M
Q3 2025$20.8MMiss by $30.7MQ2 2025$15.3MMiss by $49.7MQ1 2025$14.1MMiss by $52.6MQ4 2024$53.9MMiss by $4.1M

Diluted EPS

Q1 2026-$0.83Beat by $0.05
Q4 2025-$0.92Miss by $0.20
Q3 2025-$0.85Miss by $0.28Q2 2025-$0.75Miss by $0.90Q1 2025-$0.66Miss by $0.15Q4 2024-$0.22Beat by $0.43

Ask the moment Kura Oncology reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Kura Oncology report Q4 2025 earnings?
Kura Oncology (KURA) reported Q4 2025 earnings on March 5, 2026 before market open.
What were Kura Oncology's Q4 2025 revenue and EPS?
Kura Oncology reported revenue of $17.3M and diluted EPS of $-0.92 for Q4 2025.
Did Kura Oncology beat estimates in Q4 2025?
Revenue missed the consensus estimate of $35.4M by $18.1M. EPS missed the consensus estimate of $-0.72 by $0.20.
How did Kura Oncology's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 67.8% from $53.9M a year earlier and diluted EPS declined 318.2% from $-0.22.
Where can I find Kura Oncology's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-092465) and the 10-K periodic report (0001193125-26-092567) directly on SEC EDGAR. The filing index links above go to sec.gov.